期刊文献+

非小细胞肺癌组织miR-10b表达临床意义分析 被引量:5

Analysis of clinical and pathological significance of expression of miR-10b in the non-small cell lung cancer
原文传递
导出
摘要 目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织miR-10b的表达及其与临床病理因素的关系。方法:收集2005-01-01-2006-12-01中国医科大学附属第一医院病理科存档蜡块50例NSCLC和癌旁肺组织(距离癌组织>3cm),采用实时定量PCR检测NSCLC组织和相应癌旁组织中miR-10b的表达,分析miR-10b表达与临床病理参数的相关性,通过Kaplan-Meier进行生存分析。结果:50例NSCLC组织和相应癌旁组织中,34例癌组织miR-10b表达高于癌旁组织;癌组织miR-10b表达为1.55±0.57,相应癌旁组织为1.01±0.38,t=-2.182,P=0.034。miR-10b的表达水平与病理分期(U=189,P=0.010)和淋巴结转移(χ2=6.650,P=0.010)呈正相关,而与其他临床病理因素如性别、年龄、发病部位、病理分型和分化等均无相关性。miR-10b高表达的NSCLC患者5年生存率为4%(1/25),明显低于miR-10b低表达患者的32%(8/25),χ2=6.504,P=0.011。结论:miR-10b在NSCLC的发生发展中起着重要作用,可能成为NSCLC预后判断的指标,miRNA可能成为NSCLC分子诊断和靶向治疗的重要指标。 OBJECTIVE:To investigate the expression of MiR-10b in non-small-cell lung cancers and its correlation with clinical parameters. METHODS: Tumor specimens and adjacent normal tissues from 50 patients with NSCLC who underwent complete surgical resection were collected at First Affiliated Hospital of China Medical University from January 1st 2005 to December 1st 2006. The expressions of miR-10b in 50 NSCLC tissues and adjacent normal tissues were examined using RT-PCR. Kaplan-Meier analysis was used to compare the differences in the survival of subgroups of patients. RESULTS: In the 50 NSCLC specimens and normal lung tissues examined,miR-10b expression was higher in 34 cases of NSCLC (2-deha delta CT normal= 1.01±0.38,2-delta delta CT cancer= 1.55±0.57,t= -2. 182,P=0. 034). Overexpression of miR-10b was correlated with advanced TNM stage (U= 189,P= 0. 010)and lymph node metastasis (χ^2= 6.65, P= 0. 010). No correlation was observed .regarding gender, age, site of occurrence, histology or differentiation. The Kaplan-Meier analysis revealed that the 5-year survival rate was 4% (1/25) in patients with miR-10b overexpression and 32 % (8/25) in patients with low miR-10b expression, which was statistically significant (P= 0. 011). CONCLUSIONS: The present study reported miR-10b expression pattern in NSCLC for the first time, suggesting miR-10b plays an important role in NSCLC development.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第18期1419-1422,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(81372497) 沈阳市卫生局资助课题〔(2010)66号〕
关键词 非小细胞肺 MIR-10B MICRORNA 转移 预后 cancer, non-small cell lung miR-10b microRNA metastasis prognosis
  • 相关文献

参考文献5

二级参考文献90

  • 1Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA 2005; 11:1753-1761.
  • 2Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005; 309:1519-1524.
  • 3Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
  • 4Fitzgerald K. RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes. Curr Opin Drug Discov Dev 2005, 8:557-566.
  • 5Brennecke J, Stark A, Russell R.B, Cohen SM. Principles of microRNA-target recognition. PLoS Biol.2005; 3:e85.
  • 6Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122:6-7.
  • 7Chen CZ, Li L, Lodish HF, Bartel DE MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303:83- 86.
  • 8Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94:776-780.
  • 9Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006; 16:4-9.
  • 10Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.

共引文献270

同被引文献46

  • 1邓菊,区彩文,张建武,吴智业,刘启才,陈敏生.MiR-499促进MSCs心肌样细胞分化及其机制的初步探讨[J].广州医学院学报,2014,42(1):1-4. 被引量:2
  • 2Senapati S, Sharma P, Bafna S, et al. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer [J]. Histol Histopathol, 2008, 23(12): 1541-1552.
  • 3Yao M, Zhang W, Zhang Q, et al. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways [J]. Lung, 2011, 189(6): 53-460.
  • 4Castorina A, Giunta S. Mucin 1 (MUC1) signalling contributes to increase the resistance to cell death in human bronchial epithe- lial cells exposed to nickel acetate [J]. Biometals,2014, 27(6): 1149-1158.
  • 5Kao CJ, Wurz GT, Moniazeb AM, et al. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model [J]. Cancer Immu- nol Res, 2014, 2(6): 581- 589.
  • 6Joshi S, Kumar S, Choudhury A, et al. Altered Mucins (MUC) trafficking in benign and malignant conditions [J]. Oncotarget, 2014, 5(17): 7272-7284.
  • 7Nath S, Mukherjee P. MUC1 : a multifaeeted oneoprotein with a key role in cancer progression [J]. Trends Mol Med, 2014, 20(6) : 332-342.
  • 8Nielsen TO, Borre M, Nexo E, et al. Co-expression of HER3 and MUC1 is associated with a lavourable prognosis in patients with bladder cancer[J]. BJU international, 2015, 115(1) : 163- 165.
  • 9Gaber R, Watermann I, Kugler C, et al. Correlation of EGFR expression, gene copy number and clinicopathologieal status in NSCLC[J]. DiagnPathol, 2014, 9(1): 165.
  • 10Tofraft AC, Timsit JF, Couraud S, et al. Immunohistochemis try evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenosean study) [J]. Lung Cancer, 2014, 83(2): 182 -188.

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部